SEC filing summary
Issuer identification discrepancy: The request identifies Axe Compute Inc., but the supplied Form 10-Q is for Predictive Oncology Inc. (Nasdaq: POAI). The summary below covers the filing provided, not Axe Compute.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2023; it was signed November 13, 2023. Predictive Oncology applies AI and a biobank of more than 150,000 tumor samples to oncology drug development, alongside contract research and the STREAMWAY medical fluid-waste system. Management says it is focusing resources on its AI-based oncology business. Reportable segments are Pittsburgh, Birmingham, and Eagan.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $715,056 | $455,827 | $1,445,061 | $1,141,986 |
| Gross margin | $608,116 | $347,676 | $1,058,221 | $790,317 |
| Gross margin percentage | Approximately 85% | Approximately 76% | Approximately 73% | Approximately 69% |
| Net loss | $(3,163,450) | $(4,059,484) | $(10,508,620) | $(17,821,524) |
| Operating cash flow | Not separately provided | Not separately provided | $(10,107,030) | $(9,135,812) |
- At September 30, 2023, cash and cash equivalents were $11.92 million, down from $22.07 million at December 31, 2022. Total assets were $18.17 million and stockholders’ equity was $11.65 million.
- Current assets were $13.52 million versus current liabilities of $4.17 million. Total liabilities were $6.52 million, including a $260,220 short-term note payable bearing 9.25% interest and $2.90 million of operating lease liabilities, current and long-term combined.
- For the first nine months, investing cash outflow was $309,666 and financing cash inflow was $260,221. The latter primarily reflected financing of insurance premiums; the comparable 2022 inflow included $6.51 million from a stock-and-warrant offering.
Changes versus comparable periods
- Revenue increased 57% in Q3 and 27% for the nine-month period. Q3 growth was led by Pittsburgh, whose revenue rose to $417,096 from $172,637; Eagan remained the largest nine-month revenue contributor.
- Management attributed higher gross-margin percentages to a sales mix shift toward higher-margin contracted services.
- Net loss narrowed year over year, particularly for the nine-month period, which included a $7.23 million goodwill impairment in 2022. The 2023 nine-month period included a separate $162,905 impairment of Birmingham property and equipment.
- Operating cash use increased by about $971,000 year over year for the nine months, which management attributed primarily to operating expenses and working-capital changes.
- G&A expense declined, partly due to lower severance and depreciation and amortization. Nine-month sales and marketing expense increased, primarily with added marketing and business-development staff.
Outlook, risks, and unusual items
- Going concern: The filing states that substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance of the financial statements. Management does not expect operating revenue to sustain near-term operations and says additional capital is needed. Potential options include equity or debt financing, other financing arrangements, or monetizing businesses or assets; availability and acceptable terms are not assured.
- No quantified revenue, earnings, or cash-flow guidance is provided. Management says profitability in the near term is not assured.
- A March 2023 collaboration with Cancer Research Horizons provides for potential revenue shares from commercialization, but no revenue had been recognized under the agreement by September 30, 2023. The filing also says no collaboration royalty revenue had been recognized to date.
- Disclosure controls and procedures were deemed ineffective due to continuing material weaknesses in IT access and segregation-of-duties controls, as well as inadequate accounting resources for complex U.S. GAAP matters. Remediation efforts are underway, including additional accounting staff, but the weaknesses had not been declared remediated.
- The filing highlights risks from financing needs, AI development and adoption, regulation, competition, collaborations, and broader economic and geopolitical uncertainty. Management reported no pending legal proceedings it believed likely to cause a material adverse effect.
- The company effected a 1-for-20 reverse stock split in April 2023; reported share counts and per-share figures reflect it. Common shares outstanding were 4,033,293 at September 30 and 4,063,081 as of November 6, 2023.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Predictive Oncology Inc., not Axe Compute Inc.
- Assess cash burn, financing availability and terms, and the company’s ability to fund operations given the explicit going-concern warning.
- Track revenue quality and growth by segment, especially whether Pittsburgh AI and contract-service revenue can scale and whether margins remain improved.
- Review progress and costs for the Birmingham business after its asset impairment, and the commercial prospects of the CRH collaboration.
- Monitor remediation of the disclosed control weaknesses and any subsequent financing, asset monetization, or changes in shares outstanding.